Document Type : Original Article
Authors
1 Faculty of medicine lab of molecular genetics of aging and tumor kunming university of science and technology china
2 Lab of Molecular Genetics of Aging and Tumor, Faculty of Medicine, Kunming university of science and technology china
Abstract
Keywords
Main Subjects
“Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma”. Nature.
Afsaneh, M, et al. (2016). “The importance of stool DNA methylation in colorectal cancer diagnosis”
Agnieszka, Anna, et al. (2014). “Chromatin, Gene, and RNA Regulation Prognostic Potential of DNA Methylation and Transcript Levels of HIF1A and EPAS1 in Colorectal Cancer”
Aleksandra, M, et al. (2020). “DNA methylation analysis with methylation-sensitive high-resolution melting (MS-HRM) reveals gene panel for glioma characteristics”.
AN Carnell, et al. (2003). “Altered Methylation as a Precursor to Toxicity.” Toxical Sci 75: 229–35.
AP, Bird. (1986). “CPG-Rich Island and the Function of DNA Methylation.” Nature 321: 209–13.
B, Hendrich, Bird A. (1998). “Identification and Characterization of a Family of Mammalian Methyl-CPG Binding Protein.” Mol Cell Biol 18: 6538–47.
BD, Strahl, et al. (2000). “The Language of Histone Modification.” Nature 403: 41–45.
Bearzatto, A, et al. (2002). “P16 (INK4A) hypermethylation detected by fluorescent methylation-specific PCR in plasma from non-small cell lung cancer”. Clinical Cancer
Bin, B, et al. (2020). “Predication of survival and recurrence in patients with pancreatic cancer by integrating multi-omics data”. Scientific Reports
Brian, Z, H, et al. (2020). “Methylation of immune regulatory cytokine genes and pancreatic cancer outcome”. Epi genomic
Chen, Chen, et al. (2021). “Multi-omics analysis reveals CT83 is the most specific gene for triple-negative breast cancer and its hypo methylation is oncogenic in breast cancer”
Choks, et al. (2004). “Advances in Chromatin Remodeling and Human Diseases.” Current Opinion in Genetics and Development 14: 308–15.
Chongchang, Zhou,et al. (2018). “DNA methylation biomarkers for head and neck squamous cell carcinoma”.
Chongyang, Ren, et al. (2021). “Comprehensive analysis based on DNA methylation and RNA-seq reveals hypermethylation of the up-regulated WT1 gene with potential mechanisms in PAM50 subtypes of breast cancer” BIOINFORMATICS AND GENOMICS
Christoph, K, et al. (2011). “SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma”
Cleandra, G, et al. (2020). “Calcium signaling alteration caused by epi genetics mechanism in pancreatic cancer. From early marker to prognostic impact”. Cancers
CR, Clapie, Caims, BR. (2009). “The Biology of Chromatin Remodeling Complexes.” Biochem 78: 273–308.
DJ, Hedge, et al. (2005). “From the Margin of Genome, mobile Element Primate Evolution.” Bioassays 27: 786–821.
Dubrowinskaja, N, et al. (2014). “Neurofilament heavy polypeptide CPG island methylation associates with a prognosis of renal cell carcinoma and prediction of anti-vascular endothelial growth factor therapy response”.
E, Ballestar, et al. (2003). “Methyl-CPG Binding Protein Identify Novel Site of Epigenetic Inactivation in Human Cancer.” EMBO 22: 6335–45.
Enchong, Z, et al. (2020). “A risk prediction model of DNA methylation improves prognosis evaluation and indicates gene targets in prostate cancer”. Epi genomics
Furong, Y, et al. (2020).” Molecular regulation and clinical significance of caveolin-1 methylation in chronic lung diseases”
Galamb, O, et al. (2016). “Aberrant DNA methylation of WNT pathway genes in the development and progression of CIMP-negative colorectal cancer”
Ghavifekr, F, et al. (2013). “DNA Methylation Pattern as Important Epigenetic Criterion in Cancer.” Genetics Research International.
Ghavifekr, F, et al. (2013). “DNA Methylation Pattern as Important Epigenetic Criterion in Cancer.” Genetics Research International.
Ghavifekr, Fakhr, et al. (2013). “DNA Methylation Pattern as Important Epigenetic Criterion in Cancer.” Genetics Research International.
Graff, J., et al “Epigenetic Code in Cognition and behavior”. Behavioral Brain Research 192: 70–87.
H, NGH, Zhang, et al. (1999). “MBD2 Is Transcriptional Repressor Belonging to the MecP1 Histone Deacetylase Complex.” Nat Genetic 23: 58–61.
Hassan, A, et al. (2014). “DNA Methylation and Colorectal Cancer”, Curr Colorectal Cancer.
Hildebrandt, et al. (2010). “Hsa-miR-9 methylation status is associated with cancer development and metastatic recurrence in patients with clear cell renal cell carcinoma”. Oncogene
Irene, M, et al. (2016), “Prostate tumor DNA methylation is associated with cigarette smoking and adverse prostate cancer outcomes”. Cancer
Jessica, C, et al. (2020). “Methylation-based algorithms for diagnosis: experience from neuro-oncology”.
K, Miyamato, et al. (2005). “Diagnostic and Therapeutic Application of Epigenetic.” J Clin Oncol 35: 293–301.
K, Struhl. (1998). “Histone Acetylation and Transcriptional Regulatory Mechanism.” Gene Pev 12: 599–606.
KD, Robertson, Jones PA. (2000). “DNA Methylation.” Carcinogenesis 21: 461–67.
Ken, J, et al. (2010). “DNA methylation of HOXD3 as a marker of prostate cancer progression”. LI
Lang, W, et al. (2020). “An integrative multi-omics analysis to identify candidate DNA methylation biomarkers related to prostate cancer risk”. Nature communications
LE, Moore, et al. (2008). “Genomic DNA as Biomarker for Bladder Cancer Susceptibility in Spanish Bladder Cancer.” Lancet Oncol 9: 359–66.
Lingming, K, et al. (2019). “Multi-omics analysis based on integrated genomics, epigenomics, and transcriptomics in pancreatic cancer”. Epi genomics
Luczak, Michal W., et al (2006). “The Role of DNA Methylation in Cancer Development” 44: 143–54.
M, SZf., Pakneshan, P, et al. (2004). “DNA Methylation and Breast Cancer.” Biochem Pharmacol 68: 1187–97.
Massimo, R, et al. (2019). “Methylated DNA in Pancreatic juice distinguishes patients with pancreatic cancer from control”. Clinical Gastroenterology and hepatology.
MF, R, et al. (2003). “DNMT1 Is Required to Maintain CPG Methylation and Aberrant Gene Silencing in Human Cancer Cells.” Nat Genetic 33: 61–65.
Micha, W Ł, et al. (2006). “The Role of DNA Methylation in Cancer Development” 44 (3): 143–54.
Montavon, C, et al. (2012). “Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer”. Gynecol Oncol.
N, Fujita, et al. (2003). “Methyl CPG Binding Domain Interact with Suvh1-HP1 Heterochromatin Complex for DNA Methylation-Based Transcriptional Repression.” Biol. chem 278: 24132–38.
N, Fujita, et al. 2000. “Mechanism of Transcriptional Regulation by Methyl-CPG Binding Protein MBD1.” Mol Cell Biol 20: 5107–18.
N, Fukushima, et al. (2003). “Aberrant Methylation of (socs-1) gene in Pancreatic Ductal Neoplasm” 89: 338–43.
Natasa, v, et al. (2014). “DNA Methylation of PITX2 predicts poor survival in men with prostate cancer “. Biomarker in Medicine
Nidhi, S, et al. (2020). “Clinical significance of promoter methylation status of tumor suppressor genes in circulating DNA of pancreatic cancer patients”. Journal of cancer research and clinical oncology.
P, Pakneshan, et al. (2004). “Demethylation of urokinase Promoter as a Prognostic Marker in Patient with Breast Cancer.” Clin Cancer 10: 3035–41.
P, Pakneshan, et al. (2005). “Hypomethylation of Urokinase Promoter in Breast and Prostate Cancer.” Curr Cancer Drugs Targets 5: 471–88.
P, Pakneshan, et al. (2005). “Methylation and Inhibition of Expression of UPA by RAS Oncogene.” Carcinogenesis 26: 557–64.
PA, et al. (2001). “The Role of DNA Methylation in Mammalian Epigenetics.” Science 293: 1068–70.
PA, Tones, et al. (2007). “Epigenomics of Cancer” 128: 683–92.
Pai, SI, et al. (2009). “Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment”. Annu Rev Pathol.
Palmisano, WA, et al. (2000). “Predicting lung cancer by detecting aberrant promoter methylation in sputum”. Cancer Res
Pascale, F, et al. (2013). “Imaging, Diagnosis, Prognosis DNA Methylation of the SLC16A3 Promoter Regulates Expression of the Human Lactate Transporter MCT4 in Renal Cancer with Consequences for Clinical Outcome”.
PM, Das., Singal, R. (2004). “DNA Methylation and Cancer.” J Clin Oncol 22: 4632–42.
PW, Laid. (2005). “Cancer Epigenetics” 14: R65–76.
R, Brown., Strathdee, G. (2002). “Epigenomics and Epigenetic Therapy of Cancer” 4: 43–48.
Robertson, et al (2001). “DNA Methylation, methyltransferases and Cancer”.
RT, Utley, et al. (1998). “Transcriptional Activation Direct Histone Acetyltransferases Complexes to Nucleosome.” Nature 394: 498–502
SB, Baylin, Herman, JG. (2000). “DNA Hyper methylation in Tumorigenesis.” Trend Genetic 16: 168–74.
Shea P. C, et al. (2020). “Development of a multivariable risk model integrating urinary cell DNA methylation and cell-free RNA data for the detection of significant prostate cancer”. The Prostate
Shicheng, G, et al. (2014). “Quantitative assessment of the diagnostic role of APC promoter methylation in non-small cell lung cancer”
Sunwoo, L, et al. (2012). “Identification of GABRA1 and LAMA2 as new DNA methylation markers in colorectal cancer”
T, Jenuwain, Allis CD. (2001). “Translating Histone Code.” Science 293: 1074–80.
T, Neff, Armstrong SA. (2009). “Chromatin maps, Histone Modification and Leukemia” 23: 1243–50.
Tingting, Z, et al. (2020). “The Role of RASSF1 Methylation in Lung Carcinoma”.
Vladimir, V, et al. (2021). “Abnormal promoter DNA hypermethylation of the integrin, nidogen, and dystroglycan genes in breast cancer”
Woloszynska-Read, A, et al. (2007). “DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer”. Cancer Immun.
Xiaolong, Xu, et al. (2020). “MAGI2-AS3 inhibits breast cancer by downregulating DNA methylation of MAGI2”
Y, Saito, et al. (2002). “Overexpression of a Splice Variant of DNMT3B, DNMT3B4 Associated with DNA Pericentromeric Satellite Region during Human Hepatico carcinogenesis.” Sci USA 99: 10060–65.
Yang, L, et al. (2016). “The Clinicopathological significance of epigenetic silencing of VHL promoter and renal cell carcinoma: a meta-analysis”. Cell Physiol Biochem
Yanjun, L, et al. (2020). “Clinical Significance of P16 Gene Methylation in Lung Cancer”.
Yi, JM, et al. (2011). “Genomic and epigenomic integration identifies a prognostic signature in colon cancer”. Clin Cancer.
Yu, S, et al. (2020). “Integrated analysis of miRNAs and DNA methylation identifies miR-132-3p as a tumor suppressor in lung adenocarcinoma”.
Yun-Hua, Z, et al. (2015). “Quantitative Assessment of the Diagnostic Role of CDH13 Promoter Methylation in Lung Cancer “.
)